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lated to changes in gut function, psychoactive medications for 
central analgesia [antidepressant agents] are indicated.”
I agree that antidepressant agents can be used in the presence 
of gut dysfunction; conversely, motility-acting agents are not 
suited for severe, continuous pain with or without gut dysfunc­
tion. In addition to the study by Greenbaum and colleagues (1) 
(which showed reduction of diarrheal symptoms and the number 
of slow contractions in the rectosigmoid in patients with diar­
rhea-predominant irritable bowel syndrome), two recent studies 
have shown positive effects of antidepressant agents on small- 
bowel motility (2, 3). Imipramine, a tricyclic antidepressant agent 
with substantial anticholinergic effects, was shown to slow jejunal 
phase III propagation velocity and to prolong orocecal transit 
time in normal persons and in patients with diarrhea-predomi­
nant irritable bowel syndrome (2). In another study by the same 
research group (3), administration of paroxetine—a selective se­
rotonin reuptake inhibitor—reduced orocecal transit time in con­
trols and patients with diarrhea-predominant irritable bowel syn­
drome. No data were available on possible effects on symptoms.
To expand on my previous recommendations, I emphasize 
three points: First, antidepressant agents may improve symptoms 
of the irritable bowel syndrome by affecting motility, independent 
of mood-altering or analgesic effects, but confirmatory studies 
correlating symptoms with changes in motility and adjusting for 
depressive mood are needed. A practical approach would be to 
choose a tricyclic agent with anticholinergic properties for diar­
rhea-predominant irritable bowel syndrome and a selective sero­
tonin reuptake inhibitor for constipation-predominant irritable 
bowel syndrome.
Second, motility-altering agents are better suited for treating 
such symptoms as postprandial pain and diarrhea on an as- 
needed basis. Conversely, because antidepressant agents require 
several weeks to become effective and have a long duration of 
action, they are best prescribed when symptoms are frequent or 
continuous.
Finally, the role for motility-altering agents in other functional 
gastrointestinal disorders (for example, functional dyspepsia, 
esophageal motility disorders, and anorectal disorders) is not well 
established, requires further study, and must be determined on 
an individual basis. Because of their central analgesic effects, 
however, antidepressant agents may help when symptoms are 
severe and refractory.
Douglas A. Drossman, MD 
University of North Carolina
Chapel Hill, NC 27599
reliable IgD determinations. For example, on the basis of a case 
history and examination of a serum sample, only 6 of 85 Dutch 
laboratories could diagnose HIDS correctly. Few specialized lab­
oratories in the United States routinely measure IgD levels. In 
one study (3), laboratories were asked about measurement of 
IgD levels. All laboratories used one radial immunodiffusion 
method to assess IgD and measured only a few (<20) samples 
weekly (3). Although this method has a limited sensitivity, the 
range of serum IgD levels in HIDS is such that the diagnosis 
should be made. However, most samples in the United States are 
shipped, and IgD is susceptible to spontaneous fragmentation 
during storage due to proteolytic enzymes that are present in 
serum and may influence the results (4). This problem is avoided 
in a recently developed enzyme-linked immunosorbent assay 
(ELISA) used to determine IgD levels in human serum. We use 
a commercial monoclonal antibody that binds to Fc regions of 
IgD (Dako, Copenhagen, Denmark) and human serum with 
known IgD concentration (Behring, Marburg, Germany) as a 
reference. The lower limit of detection with our ELISA is 3
U/mL.
We found that storing IgD for as long as 5 months or repeated 
freeze-thawing cycles had no influence on the detection of IgD. 
This suggests that fragmentation does not influence the results of 
our assay. The use of an accurate ELISA for measuring IgD 
levels could enhance recognition of cases of HIDS in the United 
States.
Joost PH. Drenth, MD, PhD
Ina S. Klasen, PhD 
Jos W M  van der Meer, MD, PhD 
University Hospital St. Radboud 
6500 HB Nijmegen, the Netherlands
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Recognition of IgD and Periodic Fever
To the Editor: The hyperimmunoglobulinemia D and periodic 
fever syndrome (HIDS) is characterized by recurrent febrile at­
tacks with abdominal symptoms, joint involvement, skin lesions, 
and lymphadenopathy. The syndrome has been diagnosed in 66 
patients, most from Europe (1). The clinical picture and the 
elevated serum IgD levels (>100 U/mL) complete the diagnosis. 
Although no treatment is available, a correct diagnosis removes 
uncertainty and allows the patient to be informed on the benign 
prognosis of the syndrome.
To our knowledge, HIDS has been diagnosed in only two 
patients in the United States (2). Although population variation 
may explain the lack of cases, we believe that under-reporting of 
cases plays a substantial role. Possible reasons for such under­
reporting include lack of awareness and limited availability of
Meta-Analysis and Bouillabaisse
To the Editor: In his thoughtful editorial on the recent contro­
versy over calcium channel blockers (1), Dr. Messerli correctly 
points out that the research methods used in two recent studies
on this topic (2, are prone to various biases. Although we
agree with the general comments made in the editorial, we make
three points about the case-control Psaty and col­
leagues (2).
Dr. states that this study may have been eel to
selection bias and that hypertensive patients with coronary artery
may have been more likely to be treated with calcium
É' M. J-*antagonists than with diuretics. Psaty and 
present results that address this concern: Among persons with 
cardiovascular disease, 52.5% were receiving diuretics and only 
37.4% were receiving calcium channel blockers. Furthermore, all 
persons with known cardiovascular disease were excluded from 
the study’s principal analysis.
A second form of bias that can arise in case-control studies is 
recall bias, in which differential recollection of previous expo­
sures can lead to spurious associations between disease and 
exposure variables. Although recall bias may have affected 
recording of potential confounding variables, the exposure vari­
able of medication use was determined from computerized phar­
macy data, not from patient recall.
Finally, Psaty and colleagues did their study on a well-defined 
patient sample— enrollees in the Group Health Cooperative of
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